The present invention relates to a process for producing pharmaceutical formulations for treating Hepatitis B virus infection, comprising entecavir and pharmaceutically acceptable excipients. The process comprises wet granulation of entecavir with pharmaceutically acceptable excipients, and is very suitable to produce low dose solid formulations with improved content uniformity and stability. The invention also pertains to low dose compositions of entecavir with improved content uniformity and stability.